|
1
|
Taylor F, Huffman MD, Macedo AF, Moore TH,
Burke M, Davey Smith G, Ward K and Ebrahim S: Statins for the
primary prevention of cardiovascular disease. Cochrane Database
Syst Rev. 31:CD0048162013.
|
|
2
|
Hukkanen J, Puurunen J, Hyötyläinen T,
Savolainen MJ, Ruokonen A, Morin-Papunen L, Orešič M, Piltonen T
and Tapanainen JS: The effect of atorvastatin treatment on serum
oxysterol concentrations and cytochrome P450 3A4 activity. Br J
Clin Pharmacol. 80:473–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pignatelli P, Carnevale R, Pastori D,
Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S and
Violi F: Immediate antioxidant and antiplatelet effect of
atorvastatin via inhibition of Nox2. Circulation. 126:92–103. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yi R, Xiao-Ping G and Hui L: Atorvastatin
prevents angiotensin II-induced high permeability of human arterial
endothelial cell monolayers via ROCK signaling pathway. Biochem
Biophys Res Commun. 459:94–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oikonomou E, Siasos G, Zaromitidou M,
Hatzis G, Mourouzis K, Chrysohoou C, Zisimos K, Mazaris S, Tourikis
P, Athanasiou D, et al: Atorvastatin treatment improves endothelial
function through endothelial progenitor cells mobilization in
ischemic heart failure patients. Atherosclerosis. 238:159–164.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisen A, Leshem-Lev D, Yavin H, Orvin K,
Mager A, Rechavia E, Bental T, Dadush O, Battler A, Kornowski R and
Lev EI: Effect of high dose statin pretreatment on endothelial
progenitor cells after percutaneous coronary intervention
(HIPOCRATES Study). Cardiovasc Drugs Ther. 29:129–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ricottini E, Madonna R, Grieco D, Zoccoli
A, Stampachiacchiere B, Patti G, Tonini G, De Caterina R and Di
Sciascio G: Effect of high-dose atorvastatin reload on the release
of endothelial progenitor cells in patients on long-term statin
treatment who underwent percutaneous coronary intervention (from
the ARMYDA-EPC Study). Am J Cardiol. 117:165–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patti G, Ricottini E, Nusca A, Colonna G,
Pasceri V, D'Ambrosio A, Montinaro A and Di Sciascio G: Short-Term,
high-dose atorvastatin pretreatment to prevent contrast-induced
nephropathy in patients with acute coronary syndromes undergoing
percutaneous coronary intervention (from the ARMYDA-CIN
[atorvastatin for reduction of myocardial damage during
angioplasty–contrast-induced nephropathy] trial. Am J Cardiol.
108:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verma S and Anderson TJ: Fundamentals of
endothelial function for the clinical cardiologist. Circulation.
105:546–549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang Y, Li Y, Ye N, Guo X, Li Z, Sun G
and Sun Y: Atorvastatin inhibits the apoptosis of human umbilical
vein endothelial cells induced by angiotensin II via the
lysosomal-mitochondrial axis. Apoptosis. 21:977–996. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mehrpour M, Esclatine A, Beau I and
Codogno P: Overview of macroautophagy regulation in mammalian
cells. Cell Res. 20:748–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X, Liu H, Foyil SR, Godar RJ,
Weinheimer CJ, Hill JA and Diwan A: Impaired autophagosome
clearance contributes to cardiomyocyte death in
ischemia/reperfusion injury. Circulation. 125:3170–3181. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsui Y, Takagi H, Qu X, Abdellatif M,
Sakoda H, Asano T, Levine B and Sadoshima J: Distinct roles of
autophagy in the heart during ischemia and reperfusion: Roles of
AMP-activated protein kinase and beclin 1 in mediating autophagy.
Circ Res. 100:914–922. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gottlieb RA, Finley KD and Mentzer RM Jr:
Cardioprotection requires taking out the trash. Basic Res Cardiol.
104:169–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klee NS, McCarthy CG, Martinez-Quinones P
and Webb RC: Out of the frying pan and into the fire:
Damage-associated molecular patterns and cardiovascular toxicity
following cancer therapy. Ther Adv Cardiovasc Dis. 11:297–317.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saijonmaa O, Nyman T and Fyhrquist F:
Atorvastatin inhibits angiotensin-converting enzyme induction in
differentiating human macrophages. Am J Physiol Heart Circ Physiol.
292:H1917–H1921. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuhrman B, Koren L, Volkova N, Keidar S,
Hayek T and Aviram M: Atorvastatin therapy in hypercholesterolemic
patients suppresses cellular uptake of oxidized-LDL by
differentiating monocytes. Atherosclerosis. 164:179–185. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou J, Chen L, Fan Y, Jiang J and Wan J:
Atorvastatin increases endothelial progenitor cells in
balloon-injured mouse carotid artery. Can J Physiol Pharmacol.
92:369–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sabe AA, Elmadhun NY, Sadek AA, Chu LM,
Bianchi C and Sellke FW: Differential effects of atorvastatin on
autophagy in ischemic and nonischemic myocardium in ossabaw swine
with metabolic syndrome. J Thorac Cardiovasc Surg. 148:3172–3178.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng BC, Huang HS, Chao CM, Hsu CC, Chen
CY and Chang CP: Hypothermia may attenuate
ischemia/reperfusion-induced cardiomyocyte death by reducing
autophagy. Int J Cardiol. 168:2064–2069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goodwill AG, Frisbee SJ, Stapleton PA,
James ME and Frisbee JC: Impact of chronic anticholesterol therapy
on development of microvascular rarefaction in the metabolic
syndrome. Microcirculation. 16:667–684. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng D, Liang Q, Zeng F, Mai Z, Cai A,
Qiu R, Xu R, Li D and Mai W: Atorvastatin protects endothelium by
decreasing asymmetric dimethylarginine in dyslipidemia rats. Lipids
Health Dis. 14:412015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu H, Li D, Fang M, Han H and Wang H:
Meta-analysis of short-term high versus low doses of atorvastatin
preventing contrast-induced acute kidney injury in patients
undergoing coronary angiography/percutaneous coronary intervention.
J Clin Pharmacol. 55:123–131. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clarke AT, Johnson PC, Hall GC, Ford I and
Mills PR: High dose atorvastatin associated with increased risk of
significant hepatotoxicity in comparison to simvastatin in UK GPRD
cohort. PLoS One. 11:e01515872016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A,
Wang YP, Li PC and Wu HC: Antiangiogenic targeting liposomes
increase therapeutic efficacy for solid tumors. J Biol Chem.
284:12905–12916. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gosk S, Moos T, Gottstein C and Bendas G:
VCAM-1 directed immunoliposomes selectively target tumor
vasculature in vivo. Biochim Biophys Acta 1778. 854–863. 2008.
|
|
27
|
Li X, Wu M, Pan L and Shi J: Tumor
vascular-targeted co-delivery of anti-angiogenesis and
chemotherapeutic agents by mesoporous silica nanoparticle-based
drug delivery system for synergetic therapy of tumor. Int J
Nanomed. 11:93–105. 2015. View Article : Google Scholar
|
